Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2021.1915278
Abstract: ABSTRACT Introduction Wet age-related macular degeneration (w-AMD) represents the leading cause of visual impairment in the elderly in the developed countries. Intravitreal antivascular endothelial growth factor (VEGF) drugs are currently considered as the first-line treatment… read more here.
Keywords: treating amd; brolucizumab; anti vegf; novel anti ... See more keywords